The rs1051931 G>A Polymorphism in the PLA2G7 Gene Confers Resistance to Immunoglobulin Therapy in Kawasaki Disease in a Southern Chinese Population

Background: Kawasaki disease (KD) is a common cardiovascular disease in infants and young children, with fever, rash, and conjunctivitis as the main clinical manifestations, which can lead to the occurrence of coronary aneurysms. Intravenous immunoglobulin (IVIG) is the preferred treatment for KD pa...

Full description

Saved in:
Bibliographic Details
Main Authors: Xueping Gu (Author), Wenchun Lin (Author), Yufen Xu (Author), Di Che (Author), Yaqian Tan (Author), Zhaoliang Lu (Author), Lei Pi (Author), Lanyan Fu (Author), Huazhong Zhou (Author), Zhiyong Jiang (Author), Xiaoqiong Gu (Author)
Format: Book
Published: Frontiers Media S.A., 2020-06-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_b4cd4ea249fb4b4a804c2d13dc6b46f2
042 |a dc 
100 1 0 |a Xueping Gu  |e author 
700 1 0 |a Wenchun Lin  |e author 
700 1 0 |a Yufen Xu  |e author 
700 1 0 |a Di Che  |e author 
700 1 0 |a Yaqian Tan  |e author 
700 1 0 |a Zhaoliang Lu  |e author 
700 1 0 |a Lei Pi  |e author 
700 1 0 |a Lanyan Fu  |e author 
700 1 0 |a Huazhong Zhou  |e author 
700 1 0 |a Zhiyong Jiang  |e author 
700 1 0 |a Xiaoqiong Gu  |e author 
700 1 0 |a Xiaoqiong Gu  |e author 
245 0 0 |a The rs1051931 G>A Polymorphism in the PLA2G7 Gene Confers Resistance to Immunoglobulin Therapy in Kawasaki Disease in a Southern Chinese Population 
260 |b Frontiers Media S.A.,   |c 2020-06-01T00:00:00Z. 
500 |a 2296-2360 
500 |a 10.3389/fped.2020.00338 
520 |a Background: Kawasaki disease (KD) is a common cardiovascular disease in infants and young children, with fever, rash, and conjunctivitis as the main clinical manifestations, which can lead to the occurrence of coronary aneurysms. Intravenous immunoglobulin (IVIG) is the preferred treatment for KD patients, but 10-20% of patients are resistant to IVIG. Lipoprotein-associated phospholipase A 2 (Lp-PLA2) is a potential therapeutic target for coronary atherosclerotic heart disease, and the polymorphism of Phospholipase A2 Group VII (PLA2G7) is closely related to the activity of Lp-PLA2, of which rs1051931 is the strongest. Therefore, the rs1051931 polymorphism may be a predictor of IVIG resistance in KD patients.Methods: A total of 760 KD cases, including 148 IVIG-resistant patients and 612 IVIG-responsive patients, were genotyped for rs1051931 in PLA2G7, we compared the effects of rs1051931 on IVIG treatment in KD patients by odds ratios (OR) and 95% confidence interval (CI).Results: The homozygous mutation AA may be a protective factor for IVIG resistance in KD patients (adjusted OR = 3.47, 95% CI = 1.14-10.57, P = 0.0284) and is more evident in patients with KD aged <60 months (adjusted OR = 3.68, 95% CI = 1.10-12.28, P = 0.0399).Conclusions: The PLA2G7 rs1051931 G>A polymorphism may be suitable as a biomarker for the diagnosis or prognosis of IVIG resistance in KD in a southern Chinese population. 
546 |a EN 
690 |a rs1051931 
690 |a polymorphism 
690 |a PLA2G7 
690 |a immunoglobulin therapy 
690 |a Kawasaki disease 
690 |a Pediatrics 
690 |a RJ1-570 
655 7 |a article  |2 local 
786 0 |n Frontiers in Pediatrics, Vol 8 (2020) 
787 0 |n https://www.frontiersin.org/article/10.3389/fped.2020.00338/full 
787 0 |n https://doaj.org/toc/2296-2360 
856 4 1 |u https://doaj.org/article/b4cd4ea249fb4b4a804c2d13dc6b46f2  |z Connect to this object online.